Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice

• Published in: Molecular therapy. Methods & clinical development 2018-09, Vol.10, p.327-340
• Main Authors: Fu, Haiyan, Zaraspe, Kim, Murakami, Naoko, Meadows, Aaron S., Pineda, Ricardo J., McCarty, Douglas M., Muenzer, Joseph
• Format: Article
• Language: English
• Subjects: MPS II; neuropathic LSD; systemic rAAV9 gene delivery
• ISSN: 2329-0501; 2329-0501
• DOI: 10.1016/j.omtm.2018.07.005

No treatment is available to address the neurological need and reversibility of MPS II. We developed a scAAV9-hIDS vector to deliver the human iduronate-2-sulfatase gene and test it in mouse model. We treated MPS II mice at different disease stages with an intravenous injection of scAAV9-mCMV-hIDS at different doses. The treatments led to rapid and persistent restoration of IDS activity and the reduction of glycosaminoglycans (GAG) throughout the CNS and somatic tissues in all cohorts. Importantly, the vector treatment at up to age 6 months improved behavior performance in the Morris water maze and normalized the survival. Notably, vector treatment at age 9 months also resulted in persistent rIDS expression and GAG clearance in MPS II mice, and the majority of these animals survived within the normal range of lifespan. Notably, the vector delivery did not result in any observable adverse events or detectable systemic toxicity in any treated animal groups. We believe that we have developed a safe and effective gene therapy for treating MPS II, which led to recent IND approval for a phase 1/2 clinical trial in MPS II patients, further supporting the extended potential of the demonstrated systemic rAAV9 gene delivery platform for broad disease targets.